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Corrections
Wilson JRF, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype
arising from germline TP53 mutations. J Med Genet 2010;47:771e4. This paper contained
some inconsistencies and errors in the TP53 gene mutation annotation. The correctly
annotated mutations are shown in the revised table 1 below and are also available via the
latest update of the IARC website at http://www-p53.iarc.fr/ The conclusions drawn in the
paper are not altered by these mutation nomenclature errors.
Table 1 Tumour features of patients in the TP53 cohort
Patient Age at onset ER PR HER IHC (FISH) Grade TP53 mutation Effect
1 35 + + 3+ 3 c.672+1G/T Truncating
22 6   2+ (ampliﬁed) 3 c.112C/T, (p.Q38X) Truncating
3 24 + + 3+ 3 c.724T/C (p.C242R)* Missense
42 4   3+ 3 c.743G/A, (p.R248Q) Missense
4 (C) 31   3+ 3 As above
5 28 + + 3+ 3 c.659A/G (p.Y220C)y Missense
5 (C) 28 + + 2+ (normal range) 3 As above
62 8 +   3+ 3 c.625A/T (p.R209X) Truncating
72 9   + 3+ 3 c.919+1G/A Truncating
8 24 + + 3+ 3 c.586C/T (p.R196X) Truncating
8 (C) 27 +    2 As above
9 22 + + 3+ 3 c.437G/A (p.W146X) Truncating
*Reported as somatic mutation 13 times and germline once, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
yReported in 340 tumours and as causative mutation in 6 LFS families, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
C, Contralateral tumour; ER, Oestrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2;
IHC, Immunohistochemistry; FISH, Fluorescent In-Situ Hybridisation.
J Med Genet 2011:48:216. doi:10.1136/jmg.2010.078113corr1
Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated
consensus guidelines for clinical management and directions for future research. J Med Genet
2010;47:436e44. The name of one of the co-authors was misspelled in the author list of this
paper and should read Van Grieken NC.
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